Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.15 +0.5%	$3.31	$2.71 ▼ $4.73	$606.19M	1.2	949,163 shs	380,031 shs
ACRS Aclaris Therapeutics	$1.60 +0.9%	$1.43	$1.05 ▼ $5.17	$172.71M	0.38	1.19 million shs	308,513 shs
PHAT Phathom Pharmaceuticals	$8.16 -2.1%	$7.16	$2.21 ▼ $19.71	$567.49M	0.45	1.55 million shs	545,651 shs
RLAY Relay Therapeutics	$3.64 -0.1%	$3.25	$1.78 ▼ $10.72	$624.94M	1.62	2.10 million shs	1.96 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	-6.29%	-12.57%	-0.63%	-19.33%
ACRS Aclaris Therapeutics	+3.95%	+2.60%	+9.72%	+38.60%	+17.91%
PHAT Phathom Pharmaceuticals	-2.46%	-11.10%	-21.71%	+106.70%	-31.83%
RLAY Relay Therapeutics	+4.00%	-4.46%	+11.31%	+35.32%	-59.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.1094 of 5 stars	3.5	0.0	2.7	2.5	0.6
ACRS Aclaris Therapeutics	2.1733 of 5 stars	3.6	1.0	2.6	1.7	0.6
PHAT Phathom Pharmaceuticals	4.1874 of 5 stars	4.5	4.0	1.6	5.0	0.6
RLAY Relay Therapeutics	2.5052 of 5 stars	3.4	1.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	74.83% Upside
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	446.35% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	114.59% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	386.02% Upside

Current Analyst Ratings Breakdown

Latest ACRS, PHAT, RLAY, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	97.66	N/A	N/A	$0.51 per share	6.17
ACRS Aclaris Therapeutics	$18.72M	9.23	N/A	N/A	$1.44 per share	1.11
PHAT Phathom Pharmaceuticals	$55.25M	10.30	N/A	N/A	($3.71) per share	-2.20
RLAY Relay Therapeutics	$10.01M	62.26	N/A	N/A	$4.65 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)

Latest ACRS, PHAT, RLAY, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PHAT Phathom Pharmaceuticals	-$0.76	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
8/5/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	N/A	N/A	N/A	$0.07 million	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
ACRS Aclaris Therapeutics	N/A	5.06	5.06
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
RLAY Relay Therapeutics	N/A	19.96	19.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ACRS Aclaris Therapeutics	98.34%
PHAT Phathom Pharmaceuticals	99.01%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ACRS Aclaris Therapeutics	6.40%
PHAT Phathom Pharmaceuticals	23.00%
RLAY Relay Therapeutics	4.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable

ACRS, PHAT, RLAY, and ABUS Headlines

Recent News About These Companies

Relay Therapeutics (NASDAQ:RLAY) Shares Up 5.6% - Should You Buy?

July 16 at 1:00 PM | marketbeat.com

Private Capital Advisors Inc. Acquires Shares of 100,000 Relay Therapeutics, Inc. (NASDAQ:RLAY)

July 14 at 6:56 AM | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 61,379 Shares

July 11, 2025 | insidertrades.com

Sanjiv Patel Sells 61,379 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

July 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Consensus PT from Brokerages

July 8, 2025 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Relay Therapeutics, Inc. (RLAY) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

June 24, 2025 | insidermonkey.com

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9% - Time to Sell?

June 20, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 5.7% - Here's What Happened

June 18, 2025 | marketbeat.com

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

June 11, 2025 | globenewswire.com

Relay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast Cancer

June 2, 2025 | msn.com

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

June 2, 2025 | globenewswire.com

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025 | globenewswire.com

Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year

May 29, 2025 | investing.com

What Makes Relay Therapeutics (RLAY) a New Buy Stock

May 23, 2025 | zacks.com

Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Zura Bio (ZURA)

May 15, 2025 | theglobeandmail.com

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now

May 13, 2025 | insidermonkey.com

Relay Therapeutics Extends Cash Runway into 2029 Amid Clinical Trial Advancements

May 7, 2025 | nasdaq.com

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

May 7, 2025 | insidermonkey.com

Relay Therapeutics, Inc.: Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

May 6, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, PHAT, RLAY, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.15 +0.02 (+0.51%)

As of 02:52 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Aclaris Therapeutics NASDAQ:ACRS

$1.60 +0.02 (+0.95%)

As of 02:52 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Phathom Pharmaceuticals NASDAQ:PHAT

$8.15 -0.18 (-2.10%)

As of 02:52 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Relay Therapeutics NASDAQ:RLAY

$3.64 -0.01 (-0.14%)

As of 02:52 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time